[Public Notice+] Cellmat Therapeutics Changes to Sole Leadership Under CEO Jung Young-hoon

[Asia Economy Reporter Hyunseok Yoo] Cellma Therapeutics announced on the 16th through a public disclosure on the 14th that it has changed to a sole CEO system under Jung Young-hoon.

Currently, Dr. Yoon Byung-hak, who held the position of president at Cellma Therapeutics (hereafter 'Cellma'), has been appointed as chairman of Cellma, taking charge of management participation and leading the bio and medical business. Cellma is focusing on the development of anticancer drugs and NASH treatments through joint research and development between government-affiliated research institutes and companies. In March, it acquired Bebig, a Russian company that manufactures therapeutic radioembolization materials applied to liver cancer and prostate cancer.

A company official stated, "Starting this year, the therapeutic radioembolization materials for liver cancer will be applied to medical institutions in Russia and neighboring countries," adding, "Accordingly, Bebig's performance this year is expected to exceed last year's figures." He emphasized, "We have secured 27% of Bebig's shares in Russia, and according to the contract terms, the acquisition process to exceed 51% is proceeding smoothly."

Meanwhile, Bebig recorded sales of 16.9 billion KRW and an operating profit of 10.8 billion KRW last year, achieving an operating profit margin of over 60%.

Chairman Yoon Byung-hak expressed his aspirations, saying, "We have completed strengthening internal controls and restructuring to achieve tangible results across Cellma's pharmaceutical development and overall sales," and added, "We aim to turn a profit this year, gather the strengths of all executives and employees to create synergy, build a track record as a bio-pharmaceutical company, and become a company that everyone can trust."

This content was produced with the assistance of AI translation services.